Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Data ReadoutpositiveCardiolRx™Positive

AI Analysis

Summary

Cardiol Therapeutics announced positive Phase II MAvERIC results for CardiolRx in recurrent pericarditis, which have been accepted for publication in the Journal of the American Heart Association. The company's ongoing Phase III trial has surpassed 75% enrollment.

Clinical Trial Data

Phase

Phase II (completed); Phase III (ongoing)

Primary Endpoint

Met

Outcome Details

Phase II MAvERIC results accepted for publication in the Journal of the American Heart Association; results demonstrate CardiolRx may represent a paradigm shift in treatment of recurrent pericarditis

Importance:6/10

Sentiment:

0.80

Phase 2 DataPublicationRecurrent PericarditisPhase 3 Enrollment

Related Companies

$NASDAQ:CDIO

Read the original article

Published by PR Newswire Biotech on May 7, 2026 11:27 AM

Read Original